Study wrapper · #1339
Pharmacological management of obesity: Current landscape and emerging therapies.
Editor's note
A serviceable landscape review rather than new data. Its value is the pipeline framing: the cagrilintide-semaglutide combination and retatrutide are positioned as the agents expected to narrow the efficacy gap with bariatric surgery, while oral and longer-acting formulations are the adherence play. The regional guideline detail is a reminder that staging conventions and access differ considerably by market. Claims about approaching surgical efficacy rest on trial weight-loss percentages, not on head-to-head outcome data.
Plain-language abstract
A review of drug therapy for obesity: six agents now hold U.S. approval for long-term weight management, including semaglutide and tirzepatide, and the pipeline adds dual and triple agonists such as CagriSema, survodutide and retatrutide. The authors also note India issued an obesity guideline in January 2025 favouring earlier pharmacotherapy and stage-based classification.